AF patients may safely discontinue DOACs preoperatively
In patients with atrial fibrillation (AF) who were taking a direct oral anticoagulant (DOAC) (apixaban, dabigatran, rivaroxaban) and required anticoagulant interruption for an elective surgery/procedure, using a standardized DOAC-specific perioperative management strategy was safe for patient care, with associated low rates of major bleeding and arterial thromboembolism. More than 90% had a minimal or no residual DOAC level at the time of the surgery/procedure. T
To continue reading this article
Continue reading your article with a eMediNexus account.